Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon Licenses Gene-Targeting Tech to Pfizer

SAN FRANCISCO, Oct. 10 - Lexicon Genetics has licensed its gene-targeting isogenic DNA technology to US drug giant Pfizer, the companies announced on Wednesday.

Financial details of the agreement were not disclosed.

The non-exclusive internal research-use license is the second The Woodlands, Texas-based Lexicon has licensed to Pfizer, which also holds a non-exclusive license from Lexicon for internal research use of Lexicon's positive-negative selection technology.

"We are pleased that Pfizer has taken an additional license to our patented gene targeting technologies and believe the increased interest in our sublicense reflects the growing value that is associated with in vivo target validation," Arthur Sands, CEO of Lexicon, said in a statement.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.